Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
抑鬱症的微劑量：迷幻生物技術公司簽署了6,650萬美元的非約束性協議，以超越新型迷幻藥候選藥物的許可
Psychedelics biotech firm,Enveric Biosciences(NASDAQ:ENVB)has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs(NPP)to Vancouver, British Columbia-basedbiopharma company MindBio Therapeutics CorpCSE: MBIO, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines.
The news comes on the heels of Enveric entering into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers.
Enveric's NPP molecules are designed to be metabolized specifically to release therapeutic levels...
登入免費觀看全文
登入/註冊